seizure spectrum infographic seizure spectrum infographic

BANZEL helps
a broad range of seizure types

BANZEL was studied across 10 different seizure types associated with LGS.1


BANZEL helps
reduce severity and frequency of seizures

In a clinical trial of 138 people with LGS (ages 4-30) where BANZEL was added to their current therapy,2 BANZEL:

Reduced the severity
of seizures by


*30.6% reduction in the placebo group

Reduced frequency of
tonic-atonic seizures by


1.4% increase in the placebo group

Reduced frequency
of total seizures by


11.7% reduction in the placebo group

BANZEL for adults with LGS

The full clinical trial results were based on all of the people in the trial (including both children and adults). The clinical trial was not specifically designed to study efficacy in adults only. Actual results may vary.

The following results were based only on the adults in the trial. In the clinical trial with 138 patients, 21 adults (18 years and older) received BANZEL and 10 received placebo. These adults saw the following results3:

Reduced total
seizures by


§22.1% increase in the placebo group

Reduced tonic-atonic
seizures by


||21.7% increase in the placebo group

What to remember about treatment with BANZEL

Understand possible side effects

BANZEL is an add-on medication that can cause side effects and affect how other seizure medications work. Other medicines should not be started or stopped without talking to your doctor. Be sure to talk with your doctor for more information about the risks associated with BANZEL

Understand possible side effects

Know your medicines

Know the medicines your loved one takes. Keep a list of them and show it to your doctor and pharmacist each time you get a new medicine, including prescription and non-prescription medicines, vitamins, and supplements

Know your medicines

Keep in mind it’s an add-on

Remember, BANZEL is an add-on medicine. That means people with LGS who are still having seizures with their existing therapy may have BANZEL added to the medicines they take

Keep in mind it’s an add-on


  1. Eisai Data on File. Study No. CRUF331 0022. Release date January 26, 2005.
  2. BANZEL Prescribing Information.
  3. McMurray M. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther. 2016;5:35–43.